GENIO italiano Giuseppe Cotellessa

The paradox of population health: Focus on personalized support for the greatest impact /  Il paradosso della salute della popolazione: concentrarsi sul supporto personalizzato per il massimo impatto Segnalato dal Dott. Giuseppe Cotellessa  /  Reported by Dr. Giuseppe Cotellessa Addressing social determinants of health at the individual level will improve overall population health — but it requires a multidisciplinary team of experts working collaboratively. Abraham Maslow said in 1966, “I suppose it is tempting, if the only tool you have is a hammer, to treat everything as if it were a nail.” This mentality — known as the Law of the Instrument — indicates that people tend to rely on the tool with which they are most familiar. In a healthcare setting, that can translate into only using traditionally trained medical professionals to handle every situation, but in reality, some issues require a collaborative approach that includes other skills and experience. This is particularly releva

Allogene, Servier’s ‘off-the-shelf’ CAR-T shows high response rate in Phase I lymphoma data at ASCO /  Allogene, CAR-T "standard" di Servier mostra un alto tasso di risposta nei dati sul linfoma di fase I presso ASCO Segnalato dal Dott. Giuseppe Cotellessa /  Reported by Dr. Giuseppe Cotellessa While they have made a huge difference in the lives of patients with certain blood cancers, CAR-T cells remain a cumbersome type of therapy to give, encompassing a complex process of extraction of white blood cells, shipment and manufacturing, along with potentially serious toxicities. But data presented at a conference Friday point to a potentially much simpler alternative. South San Francisco, California-based Allogene Therapeutics and its partner, Paris-based Servier, announced the presentation of initial Phase I data on their allogeneic CAR-T therapy, ALLO-501, at the American Society of Clinical Oncology’s annual meeting, which is taking place online due to Covid-19. Whereas the

Test sierologici più efficienti grazie ad uno studio guidato da ricercatori dell’Università di Bologna /  More efficient serological tests thanks to a study led by researchers from the University of Bologna Segnalato dal Dott- Giuseppe Cotellessa / Reported by Dr. Giuseppe Cotellessa Una tecnica innovativa di elettrochemiluminescenza (ECL) permette di ottenere esami – compresi quelli per il coronavirus SARS-CoV-2 – più veloci, economici e con livelli di sensibilità molto maggiori di quelli attuali. Un gruppo di ricerca guidato da studiosi dell’Università di Bologna ha individuato un nuovo meccanismo che permette di ottenere test sierologici più veloci, economici e con livelli di sensibilità molto maggiori di quelli attuali. La novità – basata sulla tecnica dell’elettrochemiluminescenza (ECL) – è applicabile anche ai test sierologici pensati per individuare la presenza di anticorpi contro il coronavirus SARS-CoV-2. Ed è destinata ad avere un’applicazione industriale, anche grazie al coi

APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort /  Il genotipo APOE e4 prevede gravi COVID-19 nella coorte della comunità della Biobanca britannica Segnalato dal Dott. Giuseppe Cotellessa /  Reported by Dr. Giuseppe Cotellessa Double whammy A genetic variant that raises one’s risk of developing Alzheimer’s disease may also make people more susceptible to COVID-19.  People who have two copies of a version of the APOE gene called APOE4 are 14 times as likely to develop Alzheimer’s disease as people with two copies of the APOE3 version of the gene. A new study of more than 600 people in England diagnosed with COVID-19 from March 16 to April 26 found that people with two APOE4 genes also were  more than twice as likely  to test positive for the coronavirus, researchers report May 26 in the the   Journals of Gerontology: Series A .  Two previous studies showed that people with dementia were more likely to have severe cases or to die of COVID-19. This new study

Coronavirus (COVID-19) Update: FDA Authorizes First Diagnostic Test Using At-Home Collection of Saliva Specimens /   Aggiornamento di Coronavirus (COVID-19): FDA autorizza il primo test diagnostico utilizzando la raccolta domestica di campioni di saliva Segnalato dal Dott. Giuseppe Cotellessa /  Reported by Dr. Giuseppe Cotellessa Current tests to detect coronavirus antibodies — immune proteins that the body makes to help fight infection — rely on blood samples taken from a finger prick or a blood draw. But these  antibodies are also found at detectable levels in the crevices between gums and teeth  in a substance in spit that resembles blood serum, researchers report May 26 at medRxiv.org. The team took blood serum samples from 28 people who had tested positive for the virus and had those people brush their gums with a saliva collection device. The scientists then tested both the blood serum and saliva for antibodies that recognize the virus. The results suggest a potential alternati